Pivalde....another article today in Endpoints News regarding Eli Lilly backed Lycia Therapeutics and their novel approach to develop and test protein degrading drugs. As long as Alterity has patent protection, it would be interesting, if not desirable, if Stamler and Sinclair would approach Lilly and/or Lycia to collaborate on seeking their validation on the efficacy of PBT2, ATHE434, and any of the new small molecule drugs they may choose to test. Problem is and always has been our lack of manpower, financial resources, clinical labs, and time to pursue these opportunities in a multi-tasking fashion.
Today's Endpoints News Lead Article Regarding Eli Lilly Actions and Plans, page-25
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.002(40.0%) |
Mkt cap ! $31.47M | |||
| Open | High | Low | Value | Volume |
| 0.6¢ | 0.7¢ | 0.6¢ | $647.1K | 105.7M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 12944289 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 29930047 | 46 |
View Market Depth
| Last trade - 12.44pm 17/07/2024 (20 minute delay) ? |
| ATH (ASX) Chart |